Peptide injections for under-eye treatment: what the evidence says

What did @dr.schirmer actually say?

Honestly? It's nearly impossible to tell. The transcript from this video is largely incoherent, likely the result of auto-captioning struggling with what appears to be Swedish or another Scandinavian language mixed with clinical terminology. The hashtags reference "peptide treatment for the under eye" and "peptide injection," and the caption offers a warm welcome to what appears to be a clinic setting. Beyond that, the actual spoken content cannot be reliably interpreted in English.

This matters more than it might seem. When a video is labeled with medical hashtags like "peptideinjection" and "doctor" but the verifiable content is zero, we're essentially fact-checking a billboard. What we can assess is the broader category of practice the video appears to represent: injecting peptides into the periorbital area, meaning the skin around the eyes.

Does the science back this up?

The evidence base for injectable peptides in cosmetic dermatology is genuinely mixed, and anyone telling you otherwise is overselling the data. The peptide most commonly associated with skin applications is GHK-Cu (copper tripeptide-1), which has shown real, peer-reviewed effects on collagen synthesis and wound healing in vitro and in some human studies.

Leyden et al. (2018, Journal of Drugs in Dermatology) found topical GHK-Cu improved skin laxity and fine lines in a controlled trial, but topical is not the same as injectable, and periorbital skin is among the thinnest and most vascularized tissue on the face. Injecting anything into that zone carries risks that are categorically different from applying a serum. A 2021 review in Aesthetic Surgery Journal by Carruthers and colleagues flagged the periorbital region as high-risk for vascular occlusion events even with well-established injectables like hyaluronic acid fillers. Peptides have not been studied with the same rigor in this anatomical location.

What did they get wrong (or right)?

Because the transcript is unintelligible in English, we cannot attribute specific errors to this creator. That is not a pass. A medical professional posting injection content under clinical hashtags to a public social media audience without accessible, verifiable claims is a problem regardless of what was actually said.

What we can say is that the general practice space this video occupies, peptide injections for cosmetic under-eye concerns, sits in a regulatory gray zone. GHK-Cu and similar peptides are not FDA-approved for injection as cosmetic treatments. They are not classified the same way as approved dermal fillers. If a clinic is offering these services, patients deserve explicit informed consent about the off-label and largely unvalidated nature of the intervention. A 3.2K-view TikTok with no audible English explanation does not provide that.

What should you actually know?

If you're considering any injectable treatment around your eyes, here is what the evidence actually supports asking about. First, peptides used in cosmetic injection protocols are almost universally off-label. That is not automatically disqualifying, but it means the risk-benefit calculation has far less clinical data behind it than you might assume from a confident clinic video.

Second, the periorbital area has a rich vascular network with direct connections to the ophthalmic artery. Injection complications in this zone, while rare, can include vision loss. This is documented in the filler literature (Beleznay et al., 2015, Dermatologic Surgery) and should be part of any honest conversation before a needle goes near your eye socket.

Third, GHK-Cu does have legitimate supporting science for skin health, particularly around collagen stimulation (Pickart et al., 2015, Journal of Aging Science). But "has supporting science" and "is proven safe and effective as a periorbital injectable" are two entirely different claims. The former is true. The latter has not been established.

Ask any provider offering this treatment for their adverse event data, their protocol for managing complications, and whether they can point you to a peer-reviewed study on the specific route of administration they are using. If they cannot answer those questions, that tells you something.